CLINIC-LABORATORY AND ENDOSCOP FEATURES OF MOTION OF UNSPECIFIC ULCEROUS COLITIS
Keywords:
unspecific ulcerous colitis, overintestinal defeat, index of endoscope activity, index of clinical activity.Abstract
Complex clinical and laboratory-instrumental research is conducted 30 patients with an unspecific ulcerous colitis (NVC). It is exposed, that the about half of patients (53,3%) on NVC have overintestinal displays, and in 43,8% cases overintestinal defeat the two and more of organs and systems. Among of overintestinal displays NVC the defeats of liver (56,3%) which varied from reactive hepatitis (44,4%) to the autoimmune defeats of liver, were most widespread, in particular autoimmune hepatitis (33,3%) and initial sclera holangite (22,3%).
It is set that at patients on NVC with autoimmune defeat of liver, spondiloartrite and psoriasis a clinical picture did not answer endoscope therefore by us the group of overintestinal defeats which insignificantly depend on activity of inflammatory process of mucus shell in a colon is selected. For other group characteristic was appearance of displays in the moment of high activity NVC and reduction or disappearance in the stage of remiss of disease – reactive arthritis, reactive hepatitis, defeat of skin as key erythematic, defeat of mucus shell of cavity of mouth and eyes.
References
2. Дорофеев А.Э. Заболевания кишечника: Руководство для врачей / А.Э. Дорофеев, Т.Д. Звягинцева, Н.В. Харченко. – Горловка: ЧП «Ви-давництво «Ліхтар», 2010. – 552 с.
3. Електронний документ «Адаптована клінічна настанова, заснована на доказах «Неспецифічний виразковий коліт»», 2015.
4. Наказ МОЗ України від 11.02.2016 № 90 «Уніфікований клінічний протокол первинної, вторинної (спеціалізованої) та третинної (високо-спеціалізованої) медичної допомоги. Запальні захворювання кишечника (хвороба Крона, виразковий коліт)».
5. The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score / K. Ikeya, H. Hanai, K. Sugimoto [et al] // J. Cronns Colitis. – 2016. – Vol. 10(3). – P. 286-295. doi: 10.1093/ecco-jcc/jjv210.
6. Marín-Jiménez. Two-year incidence of new immune-mediated inflammatory diseases in patients with inflammatory bowel disease: A study in the AQUILES cohort / Marín-Jiménez, J.P. Gisbert, J.L. Pérez-Calle [et al.] // Gastroenterol Hepatol. – 2015. – Vol.38(10). – P. 569-74. doi: 10.1016/j.gastrohep.2015.04.003.
7. Ket S.N. Endoscopic Disease Activity in Inflammatory Bowel Disease / S.N. Ket, R. Palmer, S. Travis // Curr. Gastroenterol. Rep . – 2015. – Vol.17, No. 12. – P. 50. doi: 10.1007/s11894-015-0470-0.
8. Colonic biogeography in health and ulcerative colitis / А. Lavelle, G. Len-non, D.C. Winter [et al] // Gut. Microbes. – 2016. – Vol.7(5) . – P. 435-442.
9. The role of endoscopy in inflammatory bowel disease: GUIDELINE // A.K. Shergill, J.R. Lightdale, D.H. Bruining [et al] / 1121.e13 Gastrointest. Endoscopy. – 2015. – Vol. 81, No. 5. – P.1101-21. doi: 10.1016/j.gie. 2014.10.030.
10. Ouyang W. Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease / W. Ouyang // Cytokine Growth Factor Rev. – 2010. – Vol. 21(6). – P.435-41. doi: 10.1016/j.cytogfr.2010.10.007.
